The Evidence for Contraceptive Options and HIV Outcomes Trial

NACompletedINTERVENTIONAL
Enrollment

7,830

Participants

Timeline

Start Date

December 14, 2015

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
HIVContraception
Interventions
DRUG

DMPA

Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.

DRUG

LNG

Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.

DRUG

Copper IUD

Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.

Trial Locations (12)

2570

Aurum Klerksdorp Gavin Churchyard Legacy Centre, Klerksdorp

5201

Effective Care Research Unit (ECRU) Frere Maternity Hospital, East London

Unknown

FLAS/ICAP Clinic 1& Clinic 2, Manzini

Kisumu East Research Care and Training Program, Kisumu

Madibeng Centre for Research, Brits

Emavundleni Research Centre, Cape Town

MatCH Research Unit Commercial City, Durban

Wits Reproductive Health and HIV Institute (WRHI), Johannesburg

QM ladysmith, Ladysmith

MatCH Research Unit Edendale, Pietermaritzburg

Setshaba Research Centre, Soshanguve

University Teaching Hospital, Lusaka, Zambia, Lusaka

All Listed Sponsors
collaborator

University of Washington

OTHER

collaborator

Wits Reproductive Health and HIV Institute

OTHER

collaborator

World Health Organization

OTHER

collaborator

Madibeng Centre for Research

OTHER

collaborator

Maternal Adolescent and Child Health Research

UNKNOWN

collaborator

Qhakaza Mbokodo Research Clinic

UNKNOWN

collaborator

The Aurum Institute NPC

OTHER

collaborator

Effective Care Research Unit

OTHER

collaborator

Emavundleni Research Centre

UNKNOWN

collaborator

Setshaba Research Centre

UNKNOWN

collaborator

University of North Carolina, Chapel Hill

OTHER

collaborator

Family Life Association of Swaziland

UNKNOWN

collaborator

ICAP Columbia University

UNKNOWN

collaborator

Kenya Medical Research Institute

OTHER

lead

FHI 360

OTHER